Metagenomi Therapeutics, Inc. is an in vivo genome editing company that uses metagenomics to find and develop new CRISPR tools. The focus is on programs with clear biology and regulatory paths, with the goal of fixing genetic mutations inside the body. Its main candidate, MGX-001, is a one-time therapy meant to deliver lasting Factor VIII activity for people with hemophilia A. I follow MGX because of its unique gene-editing approach and the upcoming shift into clinical testing.
In the last 30 days, MGX fell roughly 12%, moving from a close of $0.784 on October 16, 2026, to $0.6917 on November 13, 2026. The path was uneven, with a sharp drop in mid-October, a quick lift after the FDA news, and then a retreat. Over the trailing quarter the decline reached about 44% from levels near $1.23 in mid-August, leaving the shares far below the $15.00 IPO price from February 2024.
The 30-day period started with a mid-October re-rating that took the stock from around $1.02 down to roughly $0.78 amid broader pressure on small-cap biotech names. On November 10, 2026, the FDA cleared the IND for MGX-001, opening the way for the first human trial; shares rose about 11% intraday before giving back the gain. That same day the company posted third-quarter results showing a GAAP loss of $0.56 per share that topped lowered estimates, collaboration revenue of $2.18 million (down about 75% year over year), and cash of about $101.7 million expected to last into 2028. Wells Fargo kept its Buy rating and $7.00 target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Profit-taking and revenue concerns appear to have outweighed the regulatory step in the sessions that followed.
The roughly 44% drop over three months reflects the company’s move away from legacy partnerships and toward its own pipeline, which has not yet reached the clinic. Ongoing losses and cash use have kept dilution worries alive, and the slide below $1 raises questions about Nasdaq bid-price rules. Wider caution around early-stage gene-editing stocks added to the pressure even as MGX-001 moved closer to human testing.
The main items on the horizon are clinical and financial. I’m watching closely for the start of the INTEGR8 Phase 1/2 trial for MGX-001, targeted for the first half of 2027, and the first safety and Factor VIII data expected in the second half of 2027. Preclinical data on MGX-001 is also due at the American Society of Hematology meeting. Cash burn, the $101.7 million balance, and any new financing will stay in focus, along with the stock’s position below $1 and the consensus price target near $7.00. This information is provided for educational purposes and is not investment advice.
In my own research I often turn to Tickeron’s AI tools to compare names like MGX against peers and to review automated trading approaches. The platform’s data-driven signals help put price moves and sector trends into perspective without replacing fundamental analysis.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
On November 06, 2026, the Stochastic Oscillator for MGX moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 30 instances where the indicator left the oversold zone. In 26 of the 30 cases the stock moved higher in the following days. This puts the odds of a move higher at over 87%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MGX's RSI Oscillator exited the oversold zone, 14 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for MGX just turned positive on October 29, 2026. Looking at past instances where MGX's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.
Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for MGX entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology